ClinicalTrials.gg
CompletedNCT06217952Updated Jan 23, 2024

Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers

A Phase 1 interventional study of SPL84 and Placebo in Cystic Fibrosis, sponsored by SpliSense Ltd.. Completed at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by SpliSense Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Cystic Fibrosis with a site in Israel — 2 open to participants now, 3 under way, 1 of them phase 3. Cystic Fibrosis · Israel.

Enrollment
39th of 53
32 · median 121
Started
2023
with 1 other
Phase 1
2 of 62
none open now
Registered
60th of 62
by date

Among the 62 studies in Cystic Fibrosis with a site in Israel, this one is the 39th largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1, and was the 60th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 62 studies in Cystic Fibrosis with a site in Israel are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Cystic Fibrosis with a site in Israel, or all of them as a file.
02

Study summary

This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of SPL84 single ascending doses (SAD) in healthy volunteers (HV)

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Male adults 18 to 50 years old
  • Considered healthy based on medical history, physical examination, 12-lead and clinical laboratory results
  • (BMI) 19.0-30.0 kg/m2
  • Subjects who have no difficulties in receiving drugs by inhalation

Key Exclusion Criteria:

  • A major surgical procedure or significant traumatic injury within 28 days prior to study intervention administration
  • Recent diagnosis of lung disease (\< 12 weeks from planned enrollment)
  • Any acute illness (e.g. acute infection) within 48 hours prior to the study intervention administration, which is considered of clinical significance by the Investigator.
  • Chronic respiratory disease including but not limited to obstructive airway disease such as asthma or (COPD); restrictive disease such as idiopathic pulmonary fibrosis (IPF); or pulmonary vascular disease such as pulmonary arterial hypertension (PAH).
  • History of adverse reactions during aerosol delivery of any medicinal product.
  • Total body weight ≤50 kg at screening.
  • Abnormal forced expiratory volume at one second () at screening.
  • Oxygen saturation ≤95% at screening.
  • (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP) and (total and direct) above (ULN) at screening and
  • Supine systolic blood pressure \<90 or >140 mmHg, supine diastolic blood pressure \<50 or >90 mmHg, heart rate \<45 or >100 beats per minute (bpm), or elevated body temperature (>38ºC) at screening
  • Clinically significant ECG abnormalities at screening
  • Positive for SARS-CoV-19 at screening or Day -1 (baseline).
  • Positive serology tests for (HIV), surface antigen (HBsAg), and virus (HCV) antibody at screening.
  • Positive urine drug, tobacco, and breath alcohol test result at screening or Day -1 (baseline).
  • Use of any prescription or over-the-counter (OTC) medications, including vitamins and herbal or dietary supplements within 14 days prior to dosing.
  • Subjects who have received any vaccines within 4 weeks prior to study intervention administration.
  • History or current drug/alcohol abuse (excluding use of medicinal cannabis for pain management).
  • History of smoking or vaping within 180 days (6 months) of screening
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    SPL84

    Drug: SPL84

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugSPL84

    SPL84 solution for nebulization

  • OtherPlacebo

    Placebo solution for nebulization

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)

    Incidence, nature, and severity of AEs and SAEs

    Time frame: Day 1 through Day 31

  2. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rate

    Time frame: Day 1 through Day 31

  3. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rate

    Time frame: Day 1 through Day 31

  4. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressure

    Time frame: Day 1 through Day 31

  5. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetry

    Time frame: Day 1 through Day 31

  6. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperature

    Time frame: Day 1 through Day 31

  7. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test results

    Time frame: Day 1 through Day 31

  8. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test results

    Time frame: Day 1 through Day 31

  9. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test results

    Time frame: Day 1 through Day 31

  10. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parameters

    using an ECG machine that automatically calculates heart rate and measure PR, QRS, QT, and QTc intervals

    Time frame: Day 1 through Day 31

  11. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findings

    Complete physical examinations include general appearance, head, ears, eyes, nose, throat, dentition, thyroid, chest (heart, lungs), abdomen, skin, neurological, extremities, back, neck, musculoskeletal, and lymph nodes.

    Time frame: Day 1 through Day 31

  12. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal Pulmonary function tests results

    Pulmonary function tests will be performed according to the ATS/ERS and FEV1, FVC, and FEF25-75 will be measured

    Time frame: Day 1 through Day 31

Secondary outcomes

  1. Characterization of PK of SPL84: maximum serum concentration (Cmax)

    Time frame: Predose and 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose, Day 7 and Day 31.

  2. Characterization of PK of SPL84: Time to Cmax (Tmax)

    Time frame: Predose and 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose, Day 7 and Day 31.

  3. Characterization of PK of SPL84: terminal elimination half-life (t1/2)

    Time frame: Predose and 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose, Day 7 and Day 31.

  4. Characterization of PK of SPL84: Area under the curve to the final sample (AUC0-t)

    Time frame: Predose and 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose, Day 7 and Day 31.

  5. Characterization of PK of SPL84: Area under the curve to infinity (AUC0-∞)

    Time frame: Predose and 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose, Day 7 and Day 31.

  6. Characterization of PK of SPL84: Apparent clearance (CL/F)

    Time frame: Predose and 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose, Day 7 and Day 31.

07

Study locations

1 site
  • Hadassah Ein Kerem Hospital Clinical Research Center
    Jerusalem, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Aug 2023, 6 months.

Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Jan 23, 2024
StartActual
Feb 5, 2023
Primary completionActual
Aug 6, 2023
CompletionActual
Aug 6, 2023
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06217952
Lead sponsor
SpliSense Ltd.
Responsible party
Sponsor
First posted
Jan 23, 2024
Start date
Feb 5, 2023
Primary completion
Aug 6, 2023
Completion
Aug 6, 2023
Last update
Jan 23, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion